Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yarui Ma

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Applied Optics|October 18, 2022
Interferometric laser imaging for droplet-size measurement in sprayYarui Ma, Jiwen Cui, Jiubin Tan
Frontiers of Medicine|September 14, 2023
Minimal residual disease in solid tumors: an overviewYarui Ma, Jingbo Gan, Yinlei Bai, et al.
Optics Express|April 6, 2021
Focus calibration method based on the illumination beam scanning angle modulation in a grating alignment systemTao Zhang, Yarui Ma, Jiean Li, et al.
Frontiers in Pharmacology|October 25, 2021
FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung AdenocarcinomaZeyu Zhang, Yarui Ma, Xiaolei Guo, et al.
Frontiers in Pharmacology|July 12, 2021
An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune MicroenvironmentYingxi Du, Yarui Ma, Qing Zhu, et al.
Signal Transduction and Targeted Therapy|August 20, 2020
A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivoYarui Ma, Qing Zhu, Junbo Liang, et al.
Frontiers of Medicine|December 16, 2022
GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinomaYingxi Du, Yarui Ma, Qing Zhu, et al.
Cancer Letters|February 14, 2026
SLC5A11 Mediates Metformin-Induced PD-L1 Suppression to Enhance Cancer Immunotherapy through AMPK-IRF1 SignalingYarui Ma, Xue Wang, Zhewen Wei, et al.
Cell Research|February 16, 2022
Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cellsYarui Ma, Qing Zhu, Xiaobing Wang, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Glucose restriction reprograms lipid metabolism and enhances immunotherapy through ZNRF3-Wnt-SCD signaling axisYarui Ma, Qi Zhang, Zhewen Wei, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Applied Optics|October 18, 2022
Interferometric laser imaging for droplet-size measurement in sprayYarui Ma, Jiwen Cui, Jiubin Tan
Frontiers of Medicine|September 14, 2023
Minimal residual disease in solid tumors: an overviewYarui Ma, Jingbo Gan, Yinlei Bai, et al.
Optics Express|April 6, 2021
Focus calibration method based on the illumination beam scanning angle modulation in a grating alignment systemTao Zhang, Yarui Ma, Jiean Li, et al.
Frontiers in Pharmacology|October 25, 2021
FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung AdenocarcinomaZeyu Zhang, Yarui Ma, Xiaolei Guo, et al.
Frontiers in Pharmacology|July 12, 2021
An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune MicroenvironmentYingxi Du, Yarui Ma, Qing Zhu, et al.
Signal Transduction and Targeted Therapy|August 20, 2020
A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivoYarui Ma, Qing Zhu, Junbo Liang, et al.
Frontiers of Medicine|December 16, 2022
GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinomaYingxi Du, Yarui Ma, Qing Zhu, et al.
Cancer Letters|February 14, 2026
SLC5A11 Mediates Metformin-Induced PD-L1 Suppression to Enhance Cancer Immunotherapy through AMPK-IRF1 SignalingYarui Ma, Xue Wang, Zhewen Wei, et al.
Cell Research|February 16, 2022
Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cellsYarui Ma, Qing Zhu, Xiaobing Wang, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Glucose restriction reprograms lipid metabolism and enhances immunotherapy through ZNRF3-Wnt-SCD signaling axisYarui Ma, Qi Zhang, Zhewen Wei, et al.
Pageof 2